Chang In Ho, Ahn Seung Hyun, Han June Hyun, Kim Tae-Hyoung, Kim Young Sun, Myung Soon Chul
Department of Urology, Chung-Ang University College of Medicine, Seoul, Korea.
J Urol. 2009 Feb;181(2):567-72; discussion 572-3. doi: 10.1016/j.juro.2008.10.030. Epub 2008 Dec 13.
We investigated the association between body mass index and the concentration of tumor markers including carcinoembryonic antigen, alpha-fetoprotein, the carbohydrate antigen 19-9 and prostate specific antigen, as well as the association between body mass index changes and tumor marker concentration changes in a population of healthy men.
We evaluated data on 8,776 men screened for tumor markers (carcinoembryonic antigen, alpha-fetoprotein, carbohydrate antigen 19-9 and prostate specific antigen) at least 3 times annually during an annual examination from 2001 to 2007. We assessed the tumor marker test findings for a trend in the age, alanine aminotransferase and creatinine adjusted tumor marker concentration by body mass index. We used multivariate regression analysis to determine whether a change in body mass index was associated with a tumor marker concentration change over time using calculated tumor markers, body mass index, creatinine and alanine aminotransferase concentration change per year.
After adjusting for age, creatinine and alanine aminotransferase a higher body mass index was associated with lower prostate specific antigen (p for trend <0.001), carcinoembryonic antigen (p for trend <0.001) and carbohydrate antigen 19-9 (p for trend <0.001). On multivariate regression analysis each 1 kg/m(2) of body mass index gain per year was associated with a -0.011 ng/ml change in prostate specific antigen concentration, a -0.030 ng/ml change in carcinoembryonic antigen concentration and a -0.192 IU/ml change in carbohydrate antigen 19-9 concentration per year.
In this cohort of healthy men hemodilution from increased plasma volume may be responsible for the observed decreased tumor marker concentration in men with a higher body mass index. In addition, an increase in body mass index may predict a lower tumor marker concentration in an individual.
我们在一群健康男性中研究了体重指数与包括癌胚抗原、甲胎蛋白、糖类抗原19-9和前列腺特异性抗原在内的肿瘤标志物浓度之间的关联，以及体重指数变化与肿瘤标志物浓度变化之间的关联。
我们评估了2001年至2007年年度体检期间每年至少3次筛查肿瘤标志物（癌胚抗原、甲胎蛋白、糖类抗原19-9和前列腺特异性抗原）的8776名男性的数据。我们根据体重指数评估肿瘤标志物检测结果，以了解年龄、丙氨酸转氨酶和肌酐校正后的肿瘤标志物浓度趋势。我们使用多变量回归分析，通过计算每年的肿瘤标志物、体重指数、肌酐和丙氨酸转氨酶浓度变化，来确定体重指数的变化是否与肿瘤标志物浓度随时间的变化相关。
在调整年龄、肌酐和丙氨酸转氨酶后，较高的体重指数与较低的前列腺特异性抗原（趋势p<0.001）、癌胚抗原（趋势p<0.001）和糖类抗原19-9（趋势p<0.001）相关。在多变量回归分析中，每年体重指数每增加1kg/m²，前列腺特异性抗原浓度每年变化-0.011ng/ml，癌胚抗原浓度每年变化-0.030ng/ml，糖类抗原19-9浓度每年变化-0.192IU/ml。
在这群健康男性中，血浆量增加导致的血液稀释可能是体重指数较高的男性中观察到的肿瘤标志物浓度降低的原因。此外，体重指数的增加可能预示个体肿瘤标志物浓度较低。
